In June 2013, BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) was acquired by (non_US) ANI Pharmaceuticals, Inc., in a reverse merger transaction with the acquiring firm taking over the BioSante name and publicly traded status. A pharmaceutical company, focuses on the development of products for female sexual health, menopause, contraception, and male hypogonadism, the Company's products for female sexual health, menopause, contraception and male hypogonadism include LibiGel, a once daily transdermal testosterone gel in Phase III clinical development under a special protocol assessment (SPA) for the treatment of female sexual dysfunction (FSD); Elestrin, a once daily transdermal estradiol (estrogen) gel indicated for the treatment of moderate-to-severe vasomotor symptoms; The Pill-Plus (triple component contraceptive), a once daily use of various combinations of estrogens, progestogens and androgens in development for the treatment of female sexual dysfunction (FSD) in women using oral or transdermal contraceptives, and Bio-T-Gel, a once daily transdermal testosterone gel in development for the treatment of hypogonadism, or testosterone deficiency, in men. The company licensed the technology underlying LibiGel and Elestrin from Antares Pharma, Inc.
